Liskova Alena, Samec Marek, Koklesova Lenka, Brockmueller Aranka, Zhai Kevin, Abdellatif Basma, Siddiqui Manaal, Biringer Kamil, Kudela Erik, Pec Martin, Gadanec Laura Kate, Šudomová Miroslava, Hassan Sherif T S, Zulli Anthony, Shakibaei Mehdi, Giordano Frank A, Büsselberg Dietrich, Golubnitschaja Olga, Kubatka Peter
Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovakia.
Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, 80336 Munich, Germany.
EPMA J. 2021 May 17;12(2):155-176. doi: 10.1007/s13167-021-00242-5. eCollection 2021 Jun.
Cost-efficacy of currently applied treatments is an issue in overall cancer management challenging healthcare and causing tremendous economic burden to societies around the world. Consequently, complex treatment models presenting concepts of predictive diagnostics followed by targeted prevention and treatments tailored to the personal patient profiles earn global appreciation as benefiting the patient, healthcare economy, and the society at large. In this context, application of flavonoids as a spectrum of compounds and their nano-technologically created derivatives is extensively under consideration, due to their multi-faceted anti-cancer effects applicable to the overall cost-effective cancer management, primary, secondary, and even tertiary prevention. This article analyzes most recently updated data focused on the potent capacity of flavonoids to promote anti-cancer therapeutic effects and interprets all the collected research achievements in the frame-work of predictive, preventive, and personalized (3P) medicine. Main pillars considered are: - Predictable anti-neoplastic, immune-modulating, drug-sensitizing effects; - Targeted molecular pathways to improve therapeutic outcomes by increasing sensitivity of cancer cells and reversing their resistance towards currently applied therapeutic modalities.
当前应用治疗方法的成本效益是癌症整体管理中的一个问题，对医疗保健构成挑战，并给全球社会带来巨大经济负担。因此，提出预测性诊断概念，随后进行针对性预防以及根据患者个人情况定制治疗方案的复杂治疗模式，因对患者、医疗经济和整个社会有益而获得全球认可。在这种背景下，由于类黄酮作为一类化合物及其通过纳米技术制备的衍生物具有多方面的抗癌作用，可应用于具有成本效益的癌症整体管理、一级、二级甚至三级预防，因此其应用受到广泛关注。本文分析了最新更新的数据，这些数据聚焦于类黄酮促进抗癌治疗效果的强大能力，并在预测、预防和个性化（3P）医学框架内解读所有收集到的研究成果。所考虑的主要支柱包括： - 可预测的抗肿瘤、免疫调节、药物增敏作用； - 通过提高癌细胞敏感性和逆转其对当前应用治疗方式的耐药性来改善治疗效果的靶向分子途径。
